A study on the correlation between STAT‑1 and mutant p53 expression in glioma

Yang,Wenbo; Wang,Hongwei; Ju,Haitao; Dou,Changwu

doi:10.3892/mmr.2018.8796

A study on the correlation between STAT‑1 and mutant p53 expression in glioma

Authors:
- Wenbo Yang
- Hongwei Wang
- Haitao Ju
- Changwu Dou
View Affiliations

Affiliations: Department of Neurosurgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010055, P.R. China
Published online on: March 28, 2018 https://doi.org/10.3892/mmr.2018.8796
Pages: 7807-7812

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is the most common primary brain tumor in adults and the second most common malignant tumor in children. Aberrant expression of signal transducer and activator of transcription 1 (STAT‑1) and p53 are known to affect the occurrence and progression of malignant tumors. The aim of the present study was to investigate the expression of STAT‑1 and mutant p53 gene, as well as their correlation, in patients with glioma. The present study included 50 patients who underwent glioma resection at the First Affiliated Hospital of Inner Mongolia Medical University between December 2007 and December 2011, and 10 patients with acute cerebral contusion who underwent intracerebral hematoma removal at the same hospital between January 2013 and January 2014. The expression of STAT‑1 and mutant p53 protein in patients with different grades of glioma was assessed by immunohistochemistry. Spearman's correlation coefficient was employed to examine the correlation between STAT‑1 and the grade of glioma, and mutant p53 expression. The results demonstrated that the mean expression of STAT‑1 in glioma was significantly lower compared with normal brain tissue (P<0.05). However, there was no significant difference in the STAT‑1 positive expression rate between the two groups (χ2=1.38, P>0.05). The expression score (P<0.05) and positive expression rate (χ2=31.27, P<0.05) of mutant p53 in glioma was significantly higher compared with those in normal brain tissue. Statistical analysis revealed a negative correlation between STAT‑1 expression and the grade of glioma (r=‑0.767, P<0.05). In addition, mutant p53 expression was negatively correlated with STAT‑1 expression in glioma (r=‑0.876, P<0.05). The observed negative correlation between STAT‑1 and the pathological grade of glioma suggested an association between STAT‑1 and the occurrence and development of glioma, thus revealing the potential of STAT‑1 as a diagnostic biomarker and therapeutic target for glioma.

View Figures

View References

1	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
2	Xu L, Li Z, Tao Y, Li RH, Fang F, Zhao H, Li G, Li YH, Wang J, Feng X and Pan J: Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway. J Exp Clin Cancer Res. 33:1082014. View Article : Google Scholar : PubMed/NCBI
3	Kim HS and Lee MS: STAT1 as a key modulator of cell death. Cell Signal. 19:454–465. 2007. View Article : Google Scholar : PubMed/NCBI
4	Bruyère C, Madonna S, Van Goietsenoven G, Mathieu V, Dessolin J, Kraus JL, Lefranc F and Kiss R: JLK1486, a Bis 8-hydroxyquinoline-substituted benzylamine, displays cytostatic effects in experimental gliomas through MyT1 and STAT1 activation and, to a lesser extent, PPARγ activation. Transl Oncol. 4:126–137. 2011. View Article : Google Scholar : PubMed/NCBI
5	Strobl B and Moriggl R: Recovery from chemotherapy depends on STAT1 for replenishment of B lymphopoiesis. J Leukoc Biol. 95:849–851. 2014. View Article : Google Scholar : PubMed/NCBI
6	Kim EL, Wüstenberg R, Rübsam A, Schmitz-Salue C, Warnecke G, Bücker EM, Pettkus N, Speidel D, Rohde V, Schulz-Schaeffer W, et al: Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol. 12:389–400. 2010. View Article : Google Scholar : PubMed/NCBI
7	Youlyouz-Marfak I, Gachard N, Le Clorennec C, Najjar I, Baran-Marszak F, Reminieras L, May E, Bornkamm GW, Fagard R and Feuillard J: Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell Death Differ. 15:376–385. 2008. View Article : Google Scholar : PubMed/NCBI
8	Yue X, Zhao Y, Xu Y, Zheng M, Feng Z and Hu W: Mutant p53 in cancer: Accumulation, gain-of-function, and therapy. J Mol Biol. 429:1595–1606. 2017. View Article : Google Scholar : PubMed/NCBI
9	Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, Chai RL, Ferrell RE, Zamboni B, Hunt J and Grandis JR: Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst. 98:181–189. 2006. View Article : Google Scholar : PubMed/NCBI
10	Ju H, Li X, Li H, Wang X, Wang H, Li Y, Dou C and Zhao G: Mediation of multiple pathways regulating cell proliferation, migration, laboratory investigation. J Neurosurg. 118:1239–1247. 2013. View Article : Google Scholar : PubMed/NCBI
11	Huang S, Bucana CD, Van Arsdall M and Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene. 21:2504–2512. 2002. View Article : Google Scholar : PubMed/NCBI
12	Barry SP, Townsend PA, Knight RA, Scarabelli TM, Latchman DS and Stephanou A: STAT3 modulates the DNA damage response pathway. Int J Exp Pathol. 91:506–514. 2010. View Article : Google Scholar : PubMed/NCBI
13	Thomas M, Finnegan CE, Rogers KM, Purcell JW, Trimble A, Johnston PG and Boland MP: STAT1: A modulator of chemotherapy-induced apoptosis. Cancer Res. 64:8357–8364. 2004. View Article : Google Scholar : PubMed/NCBI
14	Zhu H, Wang Z, Xu Q, Zhang Y, Zhai Y, Bai J, Liu M, Hui Z and Xu N: Inhibition of STAT1 sensitizes renal cell carcinomacells to radiotherapy and chemotherapy. Cancer Biol Ther. 13:401–407. 2012. View Article : Google Scholar : PubMed/NCBI
15	McDermott U, Longley DB, Galligan L, Allen W, Wilson T and Johnston PG: Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res. 65:8951–8960. 2005. View Article : Google Scholar : PubMed/NCBI
16	Duan X, Ponomareva L, Veeranki S, Panchanathan R, Dickerson E and Choubey D: Differential roles for the interferon-inducible IFI16 and AIM2 innate immune sensors for cytosolic DNA in cellular senescence of human fibroblasts. Mol Cancer Res. 9:589–602. 2011. View Article : Google Scholar : PubMed/NCBI
17	Liu K, Caldwell SA and Abrams SI: Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediatedcytotoxicity and altered IFN-gamma-regulated gene expression. Cancer Res. 65:4376–4388. 2005. View Article : Google Scholar : PubMed/NCBI
18	Lake RA and Robinson BW: Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer. 5:397–405. 2005. View Article : Google Scholar : PubMed/NCBI
19	Dunn GP, Koebel CM and Schreiber RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 6:836–848. 2006. View Article : Google Scholar : PubMed/NCBI
20	Watanabe T, Katayama Y, Yoshino A, Komine C and Yokoyama T: Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influenceon clinical course. Clin Cancer Res. 9:4884–4890. 2003.PubMed/NCBI
21	Wang YY, Zhang T, Li SW, Qian TY, Fan X, Peng XX, Ma J, Wang L and Jiang T: Mapping p53 mutations in low-grade glioma: A voxel-based neuroimaging analysis. AJNR Am J Neuroradiol. 36:70–76. 2015. View Article : Google Scholar : PubMed/NCBI
22	Cohen AL and Colman H: Glioma biology and molecular markers. Cancer Treat Res. 163:15–30. 2015. View Article : Google Scholar : PubMed/NCBI
23	Bell HS and Ryan KM: Targeting the p53 family for cancer therapy: ‘Big brother’ joins the fight. Cell Cycle. 6:1995–2000. 2007. View Article : Google Scholar : PubMed/NCBI
24	Fedrigo CA, Grivicich I, Schunemann DP, Chemale IM, dos Santos D, Jacovas T, Boschetti PS, Jotz GP, Filho Braga A and da Rocha AB: Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr. Radiat Oncol. 6:1562011. View Article : Google Scholar : PubMed/NCBI
25	Biddlestone-Thorpe L, Sajjad M, Rosenberg E, Beckta JM, Valerie NC, Tokarz M, Adams BR, Wagner AF, Khalil A, Gilfor D, et al: ATM kinase inhibition preferentially sensitizes p53 mutant glioma to ionizing radiation. Clin Cancer Res. 19:3189–3200. 2013. View Article : Google Scholar : PubMed/NCBI
26	Lang FF, Yung WK, Raju U, Libunao F, Terry NH and Tofilon PJ: Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J Neurosurg. 89:125–132. 1988. View Article : Google Scholar
27	Broaddus WC, Liu Y, Steele LL, Gillies GT, Lin PS, Loudon WG, Valerie K, Schmidt-Ullrich RK and Fillmore HL: Enhanced radiosensitivity of malignant glioma cell after adenoviral p53 transduction. J Neurosurg. 91:997–1004. 1999. View Article : Google Scholar : PubMed/NCBI
28	Xiang W, Zhu XL and Zhao HY: Therapeutic effect of p53 gene combined with cisplatin on experimental glioma. Chin J Clin Neurosur. 11:154–156. 2006.(In Chinese).
29	Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS and Stephanou A: STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 279:5811–5820. 2004. View Article : Google Scholar : PubMed/NCBI